GlassScriptPhysician profile
Amanda Ann Alston
NPI 1225592066
$2,427.33
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $825 · 2022: $329 · 2023: $723 · 2024: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,272.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $346.96 | 2021-2024 | Qelbree |
| Abbvie INC. | $309.45 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $308.51 | 2021-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $268.35 | 2021-2024 | Rexulti, Abilify Mycite |
| Tris Pharma INC | $246.83 | 2021-2024 | Dyanavel Xr |
| Alkermes, INC. | $164.32 | 2022-2023 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $158.39 | 2022-2023 | Invega Sustenna, Spravato |
| Lundbeck LLC | $147.71 | 2021-2023 | Rexulti |
| Corium, LLC | $90.82 | 2023-2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $85.24 | 2021-2024 | Austedo Xr |
| Neurocrine Biosciences, INC. | $61.22 | 2021-2023 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $51.93 | 2021 | |
| Neos Therapeutics, LP | $50.56 | 2021 | |
| Axsome Therapeutics, INC. | $46.12 | 2023 | Auvelity |
| Ironshore Pharmaceuticals INC. | $45.82 | 2023 | Jornay Pm |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $16.30 | 2021 | |
| Boston Scientific Corporation | $14.77 | 2021 | |
| Merck Sharp & Dohme LLC | $14.03 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Alston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.